SFC or (U)HPLC? Why Not Try Both...
The Application Notebook
Projects in drug discovery and safety constantly aim at development of novel and safer drugs, therapeutics, and diagnostics. During active pharmaceutical ingredient (API) development, drug stereoisomerism is recognized as an issue having clinical and regulatory implications. Enantiomers have essentially identical physical and chemical properties, while potentially showing large differences in toxicity.
G.J. Schad1, Y. Watabe2, and H. Terada2, 1Shimadzu Europa GmbH, 2Shimadzu Corporation
Projects in drug discovery and safety constantly aim at development of novel and safer drugs, therapeutics, and diagnostics. During active pharmaceutical ingredient (API) development, drug stereoisomerism is recognized as an issue having clinical and regulatory implications. Enantiomers have essentially identical physical and chemical properties, while potentially showing large differences in toxicity.
Stereoisomeric composition of a drug with a chiral centre should therefore be well documented. To evaluate the pharmacokinetics of a single enantiomer or any mixture of enantiomers, manufacturers must develop quantitative assays for individual enantiomers early in drug development.
One of the challenges of chiral separations is the fact that enantiomers exhibit the same physical and chemical properties, so they can only be separated in a chiral environment. For chromatographic separations chiral stationary phases are available that enable the separation of stereoisomers. However, to determine the stationary phase that offers optimum selectivity for the chiral separation problem at hand, screening runs are usually performed, testing several chiral columns at a time. Normal-phase high performance liquid chromatography (HPLC) is often the method of choice but supercritical fluid chromatography (SFC) has frequently been proven to be a superior method for the separation of chiral compounds. This application note shows an example of the method scouting for two established chiral compounds (Figure 1) using HPLC as well as SFC. Each technique has its advantages, and running the two approaches with one instrument in a single overnight sequence was easily achieved using an LC/SFC switching system, resulting in the optimum separation method for each compound.
Figure 1: Structure and chiral centre of (a) omeprazole and (b) warfarin.
Method Development
For UHPLC and SFC method scouting a Shimadzu Nexera UC LC/SFC switching system with Method Scouting Solution was used (Figure 2), consisting of a CO2 pump (LC-30ADSF), two quaternary solvent pumps (LC-30AD), an autosampler (SILâ30AC), two column ovens (CTO-20AC) including six column switching valves (FCVâ34AH), and a backpressure regulator (SFC-30A). The system was also equipped with an SPDâM20A photo diode array detector with high pressure resistant flow cell.
Figure 2: Schematic of Nexera UC LC/SFC switching system.
The stationary phases used for chiral screening for the separation of stereoisomers of warfarin and omeprazole, as well as mobile phases and separation conditions are displayed in Tables 1 and 2.
Results
A total of 36 different chromatographic conditions were evaluated in a single sequence. The dedicated Method Scouting Solution Software was used to generate screening methods and batch files automatically according to pre-set templates, to avoid human error. Ideal separation and detection conditions for each compound were determined in one overnight run. Figures 3 and 4 show the screening results for warfarin and omeprazole. It can be seen that while SFC clearly offers better separation of the warfarin isomers, omeprazole is better separated using HPLC conditions.
Figure 3: Screening results for separation of warfarin isomers.
Figure 4: Screening results for separation of omeprazole isomers.
Conclusion
The Nexera UC LC/SFC switching system in combination with the Method Scouting Solution software is the ideal tool for quick and efficient development of reliable and fast chiral separation methods in (U)HPLC or SFC mode with a single instrument.
Shimadzu Europa GmbH
Albert-Hahn-Str. 6–10, D-47269 Duisburg, Germany
Tel. +49 203 76 87 0 Fax +49 203 76 66 25
E-Mail: shimadzu@shimadzu.eu
Website: www.shimadzu.eu
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
